6.81
0.77 (12.75%)
| Penutupan Terdahulu | 6.04 |
| Buka | 6.02 |
| Jumlah Dagangan | 958,041 |
| Purata Dagangan (3B) | 512,254 |
| Modal Pasaran | 64,131,780 |
| Harga / Jualan (P/S) | 7.26 |
| Harga / Buku (P/B) | 0.540 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Nov 2025 |
| Margin Operasi (TTM) | -981.18% |
| EPS Cair (TTM) | -9.42 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 32.52% |
| Nisbah Semasa (MRQ) | 9.41 |
| Aliran Tunai Operasi (OCF TTM) | -62.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -61.34 M |
| Pulangan Atas Aset (ROA TTM) | -29.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -60.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Korro Bio, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -2.5 |
| Purata | 1.00 |
|
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 6.18% |
| % Dimiliki oleh Institusi | 104.23% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Cormorant Asset Management, Lp | 30 Sep 2025 | 465,000 |
| Qiming U.S. Ventures Management, Llc | 30 Sep 2025 | 368,085 |
| Tri Locum Partners Lp | 30 Sep 2025 | 337,764 |
| 72 Investment Holdings, Llc | 30 Sep 2025 | 276,831 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 93.00 (Clear Street, 1,265.64%) | Beli |
| Median | 8.00 (17.47%) | |
| Rendah | 7.00 (Chardan Capital, 2.79%) | Pegang |
| Purata | 36.00 (428.63%) | |
| Jumlah | 1 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 17.97 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 13 Nov 2025 | 7.00 (2.79%) | Pegang | 6.50 |
| RBC Capital | 13 Nov 2025 | 8.00 (17.47%) | Pegang | 6.50 |
| Clear Street | 31 Oct 2025 | 93.00 (1,265.64%) | Beli | 40.91 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Nov 2025 | Pengumuman | Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |